Detalles de la búsqueda
1.
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.
Clin Infect Dis
; 76(9): 1646-1654, 2023 05 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36660819
2.
Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials.
HIV Med
; 24(5): 568-579, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36411596
3.
Cabotegravir + Rilpivirine Long-Acting: Overview of Injection Guidance, Injection Site Reactions, and Best Practices for Intramuscular Injection Administration.
Open Forum Infect Dis
; 11(6): ofae282, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38882931
4.
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.
Lancet HIV
; 8(11): e668-e678, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34656207
5.
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
Lancet HIV
; 8(4): e185-e196, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33794181
6.
Regarding "A Risperidone-induced Prolactinoma Resolved When A Woman with Schizoaffective Disorder Switched to Ziprasidone: A Case Report".
Innov Clin Neurosci
; 10(2): 12-6, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23556137
Resultados
1 -
6
de 6
1
Próxima >
>>